Skip to content

Metal Panel Patch Test Study

Clinical Evaluation of Metal Panel Allergens: Safety and Efficacy Study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031220654
Enrollment
300
Registered
2023-02-22
Start date
2023-02-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin rash, Eczema Skin rash, Eczema

Interventions

Diagnostic skin test for contact allergy Apply patchtest panel 1 time
D003877
Eczema

Sponsors

Oobuchi Tomoko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The study population will consist of two groups of subjects. Group 1 will include the intended population, individuals with suspected allergic contact dermatitis to one or more of the investigational metal allergens. Subjects may have active dermatitis attributable to metal allergy at the time of enrollment or a recent history (within the past 5 years) of dermatitis that is suspected to be due to metal allergy that resolved prior to enrollment due to treatment or elimination of exposure to the suspected metal trigger. Group 2 will include patients without history or symptoms of metal-induced allergic contact dermatitis and without chronic exposure

Exclusion criteria

Exclusion criteria: Participation in SmartPractice dose response study Breastfeeding or pregnant Topical treatment with corticosteroids or immunosuppressive agents on or near the test area Systemic treatment with corticosteroids or immunosuppressive agents Treatment with UV light Dermatitis on or near the test area on the back Known or suspected infection of the skin, joints or other site(s) associated with metal exposure Fibromyalgia, chronic fatigue, depression, cognitive impairment, flu-like symptoms, diarrhea and/or headache without at least one of the symptoms related to metal exposure Psoriasis, dermatitis herpetiformis, mycosis fungoides or cutaneous T-cell lymphoma Inability to comply with patch test study requirements Participation in an investigational clinical trial 3 weeks prior to inclusion in this study. An opinion of the Investigator that deems the potential subject is unsuitable

Design outcomes

Primary

MeasureTime frame
Elicitation of allergic reaction.

Secondary

MeasureTime frame
Allergen safety

Countries

Germany, Italy, Japan, Netherland, USA

Contacts

Public ContactTomoko Oobuchi

SmartPrtactice Japan, Inc.

toobuchi@smarthealth.com+81-46-200-5617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026